Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 26, 2013, 184 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.71 to $214,535,257.08.

Highlighted Stocks Traded by Insiders:

Reynolds American (RAI) - FREE Research Report

Brown & Williamson Holdings, Inc. who is 10% Owner at Reynolds American sold 122,781 shares at $51.34 on Nov. 26, 2013. Following this transaction, the 10% Owner owned 226.5 million shares meaning that the stake was reduced by 0.05% with the 122,781 share transaction.

The shares most recently traded at $50.55, down $0.79, or 1.56% since the insider transaction. Historical insider transactions for Reynolds American go as follows:

  • 4-Week # shares sold: 387,256
  • 12-Week # shares sold: 1.3 million
  • 24-Week # shares sold: 2.7 million

The average volume for Reynolds American has been 1.5 million shares per day over the past 30 days. Reynolds American has a market cap of $27.4 billion and is part of the consumer goods sector and tobacco industry. Shares are up 22.38% year to date as of the close of trading on Tuesday.

Reynolds American Inc., through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company operates through RJR Tobacco, American Snuff, and Santa Fe segments. The stock currently has a dividend yield of 4.96%. The company has a P/E ratio of 17.8. Currently there are 2 analysts that rate Reynolds American a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RAI - FREE

TheStreet Quant Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Reynolds American Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Foot Locker (FL) - FREE Research Report

Brown Peter D who is SVP-Chief Information Officer at Foot Locker sold 2,087 shares at $39.05 on Nov. 26, 2013. Following this transaction, the SVP-Chief Information Officer owned 16,948 shares meaning that the stake was reduced by 10.96% with the 2,087 share transaction.

The shares most recently traded at $38.89, down $0.16, or 0.41% since the insider transaction. Historical insider transactions for Foot Locker go as follows:

  • 4-Week # shares sold: 8,100
  • 12-Week # shares sold: 8,100
  • 24-Week # shares sold: 102,558

The average volume for Foot Locker has been 2.0 million shares per day over the past 30 days. Foot Locker has a market cap of $5.7 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 19.89% year to date as of the close of trading on Tuesday.

Foot Locker, Inc., together with its subsidiaries, operates as a retailer of athletic footwear and apparel. The company operates in two segments, Athletic Stores and Direct-to-Customers. The stock currently has a dividend yield of 2.08%. The company has a P/E ratio of 13.8. Currently there are 8 analysts that rate Foot Locker a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FL - FREE

TheStreet Quant Ratings rates Foot Locker as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Foot Locker Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Directv (DTV) - FREE Research Report

Doyle Patrick T who is Exec. VP and CFO at Directv sold 5,000 shares at $65.39 on Nov. 26, 2013. Following this transaction, the Exec. VP and CFO owned 82,650 shares meaning that the stake was reduced by 5.7% with the 5,000 share transaction.

The shares most recently traded at $66.16, up $0.77, or 1.16% since the insider transaction. Historical insider transactions for Directv go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 30,000

The average volume for Directv has been 3.5 million shares per day over the past 30 days. Directv has a market cap of $34.2 billion and is part of the services sector and media industry. Shares are up 29.67% year to date as of the close of trading on Tuesday.

DIRECTV provides digital television entertainment in the United States and Latin America. The company engages in acquiring, promoting, selling, and distributing digital entertainment programming primarily through satellite to residential and commercial subscribers. The company has a P/E ratio of 12.6. Currently there are 12 analysts that rate Directv a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DTV - FREE

TheStreet Quant Ratings rates Directv as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Directv Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

MFA Financial (MFA) - FREE Research Report

Yadav Sunil who is Senior Vice President at MFA Financial bought 1,800 shares at $7.22 on Nov. 26, 2013. Following this transaction, the Senior Vice President owned 111,356 shares meaning that the stake was reduced by 1.64% with the 1,800 share transaction.

The shares most recently traded at $7.25, up $0.03, or 0.41% since the insider transaction. Historical insider transactions for MFA Financial go as follows:

  • 4-Week # shares bought: 12,700
  • 12-Week # shares bought: 12,700
  • 24-Week # shares bought: 14,400
  • 24-Week # shares sold: 8,000

The average volume for MFA Financial has been 3.5 million shares per day over the past 30 days. MFA Financial has a market cap of $2.7 billion and is part of the financial sector and real estate industry. Shares are down 10.97% year to date as of the close of trading on Tuesday.

MFA Financial, Inc., a real estate investment trust (REIT), invests in residential agency and non-agency mortgage-backed securities (MBS). The stock currently has a dividend yield of 12.01%. The company has a P/E ratio of 9.6. Currently there are 7 analysts that rate MFA Financial a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MFA - FREE

TheStreet Quant Ratings rates MFA Financial as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full MFA Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Boston Scientific (BSX) - FREE Research Report

Ballinger Kevin J. who is SVP & Pres, Interven Cardio at Boston Scientific sold 33,334 shares at $12.05 on Nov. 26, 2013. Following this transaction, the SVP & Pres, Interven Cardio owned 45,147 shares meaning that the stake was reduced by 42.47% with the 33,334 share transaction.

The shares most recently traded at $11.67, down $0.38, or 3.26% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 170,568
  • 12-Week # shares sold: 170,568
  • 24-Week # shares sold: 267,941

The average volume for Boston Scientific has been 14.2 million shares per day over the past 30 days. Boston Scientific has a market cap of $15.9 billion and is part of the health care sector and health services industry. Shares are up 107.5% year to date as of the close of trading on Tuesday.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null